116 related articles for article (PubMed ID: 19043877)
1. Isentress gets another good grade.
Dalton P
Proj Inf Perspect; 2008 Sep; (46):9. PubMed ID: 19043877
[No Abstract] [Full Text] [Related]
2. Study supports use of Isentress for first line treatment.
Proj Inf Perspect; 2008 Dec; (47):9. PubMed ID: 19227560
[No Abstract] [Full Text] [Related]
3. Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.
Proj Inf Perspect; 2009 Mar; (48):6. PubMed ID: 19492458
[No Abstract] [Full Text] [Related]
4. [Integrase inhibition--a new mode of action in HIV therapy].
van Lunzen J; Degen O
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567
[No Abstract] [Full Text] [Related]
5. [Integrase inhibition].
Bogner JR
MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
[No Abstract] [Full Text] [Related]
6. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
7. [Integrase inhibitor: raltegravir also as first line therapy].
MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
[No Abstract] [Full Text] [Related]
8. FDA notifications. Raltegravir indication extended for treatment-naive patients.
AIDS Alert; 2009 Aug; 24(8):93. PubMed ID: 19705587
[No Abstract] [Full Text] [Related]
9. Study explains Isentress' excellent resistance profile.
Proj Inf Perspect; 2008 Dec; (47):3. PubMed ID: 19226674
[No Abstract] [Full Text] [Related]
10. One-on-one with Joe Eron, M.D. An update on Isentress (raltegravir) data, including some unexpected results. Interview by Jeff Berry.
Eron J
Posit Aware; 2009; 20(3):46-7. PubMed ID: 19492451
[No Abstract] [Full Text] [Related]
11. Integrase inhibitors for the treatment of HIV infection.
Pace P; Rowley M
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
[TBL] [Abstract][Full Text] [Related]
12. [A clinical study with an HIV integrase inhibitor].
Winckler T
Pharm Unserer Zeit; 2007; 36(4):251-2. PubMed ID: 17623312
[No Abstract] [Full Text] [Related]
13. Anti-HIV agents. Raltegravir (Isentress)--results after one year.
TreatmentUpdate; 2007; 19(6):8-9. PubMed ID: 18041152
[No Abstract] [Full Text] [Related]
14. [Raltegravir: initially as effective as standard therapy].
Warpakowski A
MMW Fortschr Med; 2010 Apr; 152(17):49. PubMed ID: 20509262
[No Abstract] [Full Text] [Related]
15. [Raltegravir as first integrase inhibitor in an HIV-infection].
Papendorp SG; Brinkman K
Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
[No Abstract] [Full Text] [Related]
16. [Raltegravir - long lasting effectiveness, well tolerated and well combined].
MMW Fortschr Med; 2013 Jun; 155 Suppl 1():30-1. PubMed ID: 23961651
[No Abstract] [Full Text] [Related]
17. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.
Croce F; Vitello P; Dalla Pria A; Riva A; Galli M; Antinori S
Int J STD AIDS; 2010 Nov; 21(11):783-5. PubMed ID: 21187364
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV agents. Integrase inhibitor raltegravir makes its mark.
TreatmentUpdate; 2007 Feb; 19(2):8-9. PubMed ID: 17447316
[No Abstract] [Full Text] [Related]
19. S-1360 Shionogi-GlaxoSmithKline.
Billich A
Curr Opin Investig Drugs; 2003 Feb; 4(2):206-9. PubMed ID: 12669383
[TBL] [Abstract][Full Text] [Related]
20. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection.
Rowley M
Prog Med Chem; 2008; 46():1-28. PubMed ID: 18381123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
